The 'weight-loss trade' has stalled. What it will take to revive investor interest
The 'weight-loss trade' has stalled. What it will take to revive investor interest
Eli Lilly looks to extend its winning streak over the broader market to 6 years
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
FDA says Eli Lilly's weight loss drug Zepbound is no longer in shortage
Why Americans are outraged over health insurance — and what could change
